{"altmetric_id":2013148,"counts":{"readers":{"mendeley":5,"citeulike":0,"connotea":0},"total":{"posts_count":1},"twitter":{"unique_users_count":1,"unique_users":["NatRevUrol"],"posts_count":1}},"citation":{"abstract":"The pursuit of reduced-intensity treatments for testicular cancer continued with vigour in 2013. For those with metastatic disease and poor prognoses, an alternative to bleomycin, etoposide and cisplatin chemotherapy emerged. These advances suggest we are making progress by reducing treatment intensity with personalized approaches for this highly curable malignancy.","abstract_source":"pubmed","altmetric_jid":"4f6fa62f3cf058f610008260","authors":["Jan Oldenburg","Sophie D. Foss\u00e5"],"doi":"10.1038\/nrurol.2013.298","endpage":"","first_seen_on":"2013-12-31T15:55:37+00:00","issns":["1759-4812","1759-4820"],"journal":"Nature Reviews Urology","last_mentioned_on":1388505326,"links":["http:\/\/www.nature.com\/nrurol\/journal\/vaop\/ncurrent\/full\/nrurol.2013.298.html?WT.mc_id=TWT_NatRevUrol"],"pmid":"24366345","pubdate":"2013-12-24T00:00:00+00:00","publisher":"Nature Publishing Group","publisher_subjects":[{"name":"Testicular cancer","scheme":"npg"},{"name":"Germ cell tumours","scheme":"npg"},{"name":"Clinical Sciences","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"startpage":"","title":"Testicular cancer in 2013: Towards personalized medicine[mdash]are we there yet?","type":"article","uri":"http:\/\/www.nature.com\/doifinder\/10.1038\/nrurol.2013.298","mendeley_url":"http:\/\/www.mendeley.com\/research\/testicular-cancer-2013-towards-personalized-medicineare-we"},"altmetric_score":{"score":0.5,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":0.5},"context_for_score":{"all":{"total_number_of_other_articles":4507509,"mean":5.1386389830674,"rank":3064041,"this_scored_higher_than_pct":20,"this_scored_higher_than":943581,"rank_type":"exact","sample_size":4507509,"percentile":20},"similar_age_3m":{"total_number_of_other_articles":122060,"mean":7.6526139326067,"rank":79943,"this_scored_higher_than_pct":22,"this_scored_higher_than":27167,"rank_type":"exact","sample_size":122060,"percentile":22},"this_journal":{"total_number_of_other_articles":869,"mean":4.6298248847926,"rank":646,"this_scored_higher_than_pct":13,"this_scored_higher_than":120,"rank_type":"exact","sample_size":869,"percentile":13},"similar_age_this_journal_3m":{"total_number_of_other_articles":44,"mean":1.056976744186,"rank":20,"this_scored_higher_than_pct":38,"this_scored_higher_than":17,"rank_type":"exact","sample_size":44,"percentile":38}}},"demographics":{"poster_types":{"member_of_the_public":1},"users":{"twitter":{"cohorts":{"Members of the public":1}},"mendeley":{"by_status":{"Librarian":1,"Researcher":2,"Student  > Doctoral Student":2},"by_discipline":{"Medicine and Dentistry":2,"Chemistry":1,"Psychology":1,"Computer Science":1}}},"geo":{"twitter":{"GB":1}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/NatRevUrol\/status\/418047755299614720","license":"public","citation_ids":[2013148],"posted_on":"2013-12-31T15:55:26+00:00","author":{"name":"NatureReviewsUrology","url":"http:\/\/www.nature.com\/nrurol","image":"https:\/\/pbs.twimg.com\/profile_images\/1630686023\/nrurol_Twitter_logo_normal.jpg","description":"Urology news, conference tweets & editors' picks from Chief Ed Annette Fenner [AF] & Senior Eds Lou Stone [LS] and Clemens Thoma [CT]","id_on_source":"NatRevUrol","tweeter_id":"407730106","geo":{"lt":51.50853,"ln":-0.12574,"country":"GB"},"followers":6680},"tweet_id":"418047755299614720"}]}}